Two Rutgers engineers specializing in the process of making drugs derived from living organisms have created an analytical tool they expect will accelerate the discovery and production of biologic drugs that are often at the cutting edge of biomedical research. In an article that is the cover story in the American Chemical Society journalAnalytical Chemistry, the researchers provide details about what they call an “automated toolkit” – or, more formally, the N-GLYcanyzer– and its potential to rapidly monitor drug quality during production of biologics, which can range from vaccines to recombinant therapeutic proteins. While most biologics are tested at the end of the manufacturing process for quality and uniformity, the Rutgers toolkit can monitor biologics as they are being produced and enable the drugs to meet the quality compliance needs of regulatory agencies, such as the U.S. Food and Drug Administration (FDA). To read the full story.